Antiangiogenesis: A new approach to the treatment of lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 454-455

  Ganjoo, Kristen ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BLOOD CLOTTING FACTOR 8 ANTIBODY; CD31 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NONHODGKIN LYMPHOMA; NOTE; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SURVIVAL RATE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33947669379     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701200059     Document Type: Note

References (8)

1. Jørgensen, J. M., Sarensen, F. B., Bendix, K., Nielsen, J. L., Olsen, M. L. and Funder, A MD (2007) Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma, 48:3, pp. 584-595.
2. Arias, V. and Soares, F. A. (2000) Vascular density (tumor angiogenesis) in non-Hodgkin's lymphoma and florid follicular hyperplasia: A morphometric study. Leuk Lymphoma, 40, pp. 157-166.
3. Niitsu, N., Okamoto, M., Nakamine, H., Yoshino, T., Tamaru, J. and Nakamura, S. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukine-6 as independent predictors of prognosis in non-Hodgkin's lymphoma. Eur J Haemotol, 68, pp. 91-100.
4. Salven, P., Orpana, A., Teerenhovi, L. and Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: A single institution study of 200 patients. Blood, 96, pp. 3712-3718.
5. Levine, A. M., Tulpule, A., Quinn, D. I., Gorospe, G 3rd, Smith, D. L. and Hornor, L. (2006) Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol, 24, pp. 1712-1719.
6. Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A. and Weienbach, J. (2006) Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma, 47, pp. 998-1005.
7. Stopeck, A., Iannone, M., Rimsza, L., Miller, T., Fisher, R. and Bellamy, W. (2004) Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: correlative studies from the SWOG S0108 trial. Blood, 104, p. 629a.
8. Stopeck, A., Bellamy, W., Unger, J., Rimsza, L., Iannone, M. and Fisher, R. I. (2005) Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol, 23, p. 583s.